Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
The present invention relates in general to the field of modulators of the innate immune system, particularly to pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof, preferably suitable for local administration, such as, intravesical administration. In addition, the present invention concerns the use of imidazoquinolin(amines) and derivatives thereof for intravesical treatment of bladder diseases, such as, for example, bladder cancer and cystitis. The present invention furthermore comprises methods of treatment for these diseases as well as methods of administration of the inventive pharmaceutical compositions.
1. A pharmaceutical composition comprising imiquimod, lactic acid, a polymer and cyclodextrin, wherein the polymer consists of Poloxamer 407 in an amount of 11% (w/v) to 18% (w/v), and the composition is for bladder instillation.
2. The pharmaceutical composition of claim 1 , wherein the lactic acid is at a concentration of about 0.025 M to about 0.200 M.
3. The pharmaceutical composition of claim 2 , wherein the lactic acid is at a concentration of about 0.075 M to about 0.125 M.
4. The pharmaceutical composition of claim 1 , wherein the imiquimod is in an amount of about 0.005% (w/v) to about 5% (w/v).
5. The pharmaceutical composition of claim 4 , wherein the imiquimod is in an amount of about 0.1% (w/v) to about 1% (w/v).
6. The pharmaceutical composition of claim 1 , wherein the cyclodextrin is selected from α-cyclodextrins, β-cyclodextrins, γ-cyclodextrins, δ-cyclodextrins, ε-cyclodextrins, and hydroxypropyl-β-cyclodextrin (HP-β-CD).
7. The pharmaceutical composition of claim 6 , wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD).
8. The pharmaceutical composition of claim 1 , wherein the cyclodextrin in an amount of about 0.1% (w/v) to about 30% (w/v).
9. The pharmaceutical composition of claim 8 , wherein the cyclodextrin in an amount of about 2% (w/v) to about 6% (w/v).
10. The pharmaceutical composition of claim 1 , wherein the Poloxamer 407 is in an amount of 11% (w/v) to 17% (w/v).
11. The pharmaceutical composition of claim 10 , wherein the Poloxamer 407 is in an amount of 11% (w/v) to 16% (w/v).
12. The pharmaceutical composition of claim 1 , wherein the composition is aqueous.
13. A pharmaceutical composition comprising imiquimod in an amount of about 0.1% (w/v) to about 1% (w/v), lactic acid in a concentration of about 0.075 M to about 0.125 M, cyclodextrin in an amount of about 2% (w/v) to about 6% (w/v), and a polymer consisting of Poloxamer 407 in an amount of 11% (w/v) to 18% (w/v), and the composition is aqueous and is for bladder instillation.